Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 856 to 870 of 1244 results for pathway

  1. Lapatinib or trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone-receptor-positive breast cancer that overexpresses HER2 (TA257)

    Evidence-based recommendations on lapatinib (Tyverb) and trastuzumab (Herceptin) for treating metastatic hormone receptor-positive breast cancer that overexpresses HER2 in adults.

    Technology appraisal guidance
    Published
    27 June 2012
    View recommendations

    Sections for TA257

  2. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (TA375)

    Evidence-based recommendations on adalimumab (Humira), etanercept (Enbrel), infliximab (Remicade, Remsima, Inflectra), certolizumab pegol (Cimzia), golimumab (Simponi), tocilizumab (RoActemra) and abatacept (Orencia). These drugs are for adults with severe rheumatoid arthritis who have tried conventional DMARDs only but they have not worked.

    Technology appraisal guidance
    Published
    26 January 2016
    View recommendations

    Sections for TA375

  3. Guide to the methods of technology appraisal 2013 (PMG9)

    Guide to the methods of technology appraisal 2013

  4. High-throughput non-invasive prenatal testing for fetal RHD genotype (DG25)

    Evidence-based recommendations on high-throughput non-invasive prenatal testing (NIPT) for fetal RHD genotype

    Diagnostics guidance
    Published
    9 November 2016
    View recommendations

    Sections for DG25

  5. Kendall DL for ECG monitoring in people having cardiac surgery (MIB177)

    NICE has developed a medtech innovation briefing (MIB) on Kendall DL for ECG monitoring in people having cardiac surgery .

    Medtech innovation briefing
    Published
    18 March 2019

  6. StoneChecker for kidney stone evaluation (MIB171)

    NICE has developed a medtech innovation briefing (MIB) on StoneChecker for kidney stone evaluation .

    Medtech innovation briefing
    Published
    1 February 2019

  7. Helge for detecting haemolysis (MIB225)

    NICE has developed a medtech innovation briefing (MIB) on Helge for detecting haemolysis .

    Medtech innovation briefing
    Published
    1 September 2020

  8. Everolimus with exemestane for treating advanced breast cancer after endocrine therapy (TA421)

    Evidence-based recommendations on everolimus (Afinitor) for treating advanced breast cancer in adults after endocrine therapy.

    Technology appraisal guidance
    Published
    21 December 2016
    View recommendations

    Sections for TA421

  9. Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia (TA394)

    Evidence-based recommendations on evolocumab (Repatha) for treating primary hypercholesterolaemia or mixed dyslipidaemia in adults.

    Technology appraisal guidance
    Published
    22 June 2016
    View recommendations

    Sections for TA394

  10. Teduglutide for treating short bowel syndrome (TA804)

    Evidence-based recommendations on teduglutide (Resvestive) for treating short bowel syndrome in people 1 year and above.

    Technology appraisal guidance
    Published
    30 June 2022
    View recommendations

    Sections for TA804

  11. Eating disorders (QS175)

    This quality standard covers assessment, treatment, monitoring and care for children, young people and adults with an eating disorder. It describes high-quality care in priority areas for improvement.

    Quality standard
    Published
    21 September 2018
    View quality statements

    Sections for QS175

  12. Serious eye disorders (QS180)

    This quality standard covers the diagnosis and management of cataracts, glaucoma and age-related macular degeneration (AMD) and the prevention of sight loss. It describes high-quality care in priority areas for improvement.

    Quality standard
    Published
    12 February 2019
    View quality statements

    Sections for QS180

  13. Guidance on the use of paclitaxel in the treatment of ovarian cancer (TA55)

    Evidence-based recommendations on paclitaxel for treating ovarian cancer in adults.

    Technology appraisal guidance
    Last updated
    1 May 2005
    View recommendations

    Sections for TA55

  14. The RhinoChill intranasal cooling system for reducing temperature after cardiac arrest (MIB4)

    NICE has developed a Medtech Innovation Briefing (MIB) on the RhinoChill intranasal cooling system

    Medtech innovation briefing
    Published
    1 February 2014

  15. The committee recommends more research on: the accuracy of PredictSURE IBD and IBDX tests in identifying people at high or low risk of following a severe course of Crohn's disease how PredictSURE IBD and IBDX tests, when used alongside clinical features, affect clinical decisions about whether step-up or top-down treatment is offered the clinical outcomes and costs resulting from a top-down treatment strategy compared with a step-up treatment strategy how PredictSURE IBD and IBDX tests affect clinical outcomes once someone has been assigned to top-down or step-up treatment, considering the different pathways that children and adults may follow.

    been assigned to top-down or step-up treatment, considering the different pathways that children and adults may follow. Any explanatory...

    Research recommendation
    Published
    24 March 2022